Lunesta Scripts Limited To Five Refills Under Proposed DEA Scheduling
This article was originally published in The Pink Sheet Daily
Executive Summary
DEA proposes scheduling Sepracor’s sleep aid as a Schedule IV controlled substance limited to five refills in a six-month period. Under the proposed rule, all dispensers and distributors of Lunesta would be required to be registered and to keep on hand inventories of eszopiclone.
You may also be interested in...
Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
The unbranded spot tells patients suffering from insomnia to stay tuned for more information coming April 24 about “something on its way that could change your nights.” The ad first aired April 10. Sepracor is also planning to discuss labeling revisions with FDA based on its second six-month trial.
Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
The unbranded spot tells patients suffering from insomnia to stay tuned for more information coming April 24 about “something on its way that could change your nights.” The ad first aired April 10. Sepracor is also planning to discuss labeling revisions with FDA based on its second six-month trial.
Lunesta Schedule IV Placement Effective Immediately, DEA Says
The Drug Enforcement Administration's final rule designates Lunesta (eszoplicone) as a Schedule IV controlled substance. Sepracor planned to launch the insomnia agent on the day of the ruling.